首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1963831

癲癇藥物市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物、分銷管道、地區和競爭格局分類，2021-2031年

Epilepsy Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drugs, By Distribution Channel, By Region & Competition, 2021-2031F

出版日期: 2026年01月19日 | 出版商:

TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球癲癇治療市場預計將從 2025 年的 71.6 億美元成長到 2031 年的 85.9 億美元，複合年成長率為 3.08%。

該產業涵蓋抗驚厥藥物和抗癲癇藥物的研發和市場推廣，旨在調節神經活動並控制神經性癲癇發作的頻率。推動這一成長的關鍵因素包括全球慢性腦部疾病患病率的上升以及政府主導的診斷舉措的廣泛實施。世界衛生組織（世衛組織）預測，到2024年，全球將有約5,000萬人患有癲癇，凸顯了對有效治療性介入日益成長的迫切需求。

市場概覽
預測期	2027-2031
市場規模：2025年	71.6億美元
市場規模：2031年	85.9億美元
複合年成長率：2026-2031年	3.08%
成長最快的細分市場	第二代抗癲癇藥物
最大的市場	北美洲

阻礙市場發展的主要障礙是發展中國家醫療基礎設施不足，導致治療資源嚴重匱乏。這種差距限制了患者獲得基本藥物的機會，也阻礙了製藥公司在新興經濟體的商業性擴張。世界衛生組織的數據顯示，到2024年，低收入國家約75%的癲癇患者將無法獲得必要的醫療服務，這將嚴重阻礙抗癲癇藥物的公平分配。

市場促進因素

全球癲癇和癲癇發作性疾病發生率的上升是市場擴張的主要驅動力，導致需要長期藥物治療的患者人數不斷增加。由於遺傳因素和後天性腦損傷導致盛行率上升，所有患者群體對有效抗癲癇藥物的需求日益成長。為了滿足不斷擴大的患者群體，需要提高基本藥物的產能並建立永續的供應鏈。正如美國疾病管制與預防中心 (CDC) 於 2024 年 5 月發布的最新版《癲癇基礎知識》中所述，美國約有 300 萬成年人患有活動性癲癇，凸顯了對癲癇控制干涉措施的巨大需求。這對製造商至關重要，因為他們需要確保穩定的商業性基礎，以擴展其治療產品組合。

同時，第三代抗癲癇藥物的進步正在提升市場價值，滿足了難治性癲癇治療領域尚未充分滿足的重大需求。這些新型製劑具有精準的作用機制，可針對特定症候群，為對標準治療無效的患者提供了可行的選擇。這些特效療法的商業性成功凸顯了市場正從學名藥轉向高價值療法。例如，Jazz Pharmaceuticals在2024年11月發布的2024年第三季財報中披露，其Epidiolex淨銷售額成長18%，達到2.516億美元。同樣，UCB在2024年7月發布的2024年第一季財報中宣布，其Fintepla上半年淨銷售額達到1.54億歐元。這反映了由針對複雜神經系統疾病的創新藥物所驅動的強勁成長勢頭。

市場挑戰

發展中地區治療選擇上的嚴重差異以及醫療基礎設施的不足，是限制全球癲癇治療市場發展的主要阻礙因素。這種結構性缺陷直接限制了製藥公司的商業性潛力，從物理和經濟層面阻礙了抗癲癇藥物向全球絕大多數患者的流通。由於缺乏健全的診斷網路和可靠的供應鏈，數百萬潛在患者仍未得到診斷或無法獲得持續的處方箋，這大大縮小了可有效開拓的市場。難以打入高發新興市場導致收入停滯不前，迫使企業過度依賴已飽和的已開發經濟體。

近期藥物供應數據凸顯了這項限制的嚴重性。根據國際癲癇聯盟統計，截至2023年，全球僅有五分之一的癲癇患者能夠獲得價格合理的抗癲癇藥物。這項數據表明，儘管癲癇病發病率很高，但該行業的實際商業性覆蓋範圍實際上僅佔總需求的一小部分。因此，這種差距對市場估值和擴張設定了明確的上限，直接限制了該行業的財務表現。

市場趨勢

數位健康和穿戴式監測技術的融合正在重塑患者照護的基礎，將治療重點從被動應對轉向預防和全面管理。這一趨勢包括引入人工智慧驅動的平台和智慧型設備，這些平台和設備能夠持續追蹤癲癇發作活動，並透過實現患者和神經科之間的即時數據共用來最佳化治療效果。製藥公司正積極利用這種協同效應，建立專門負責數位療法的商業部門，從而拓展其價值提案，使其超越傳統藥物的範疇。例如，SK Biopharmaceuticals 於 2025 年 10 月與 Europharma 成立了一家合資企業 Mentiscare，旨在將基於人工智慧的癲癇管理平台商業化，該平台提供癲癇發作檢測和個人化護理解決方案。

同時，為了幫助那些對現有標準療法無效的患者，抗藥性癲癇治療藥物的研發工作也正在加速。製藥公司正大力投資其臨床研發管線，開發具有獨特作用機制的新型小分子候選藥物，例如鉀通道開放劑，以治療局部癲癇發作和其他難治性癲癇。這項策略性舉措得到了大量資金的支持，用於開展旨在將下一代療法推向市場的後期臨床試驗。根據氙氣 Pharmaceuticals公司於2025年2月發布的《2024年第四季及全年財務表現報告》，該公司報告其現金及投資頭寸為7.544億美元，主要用於支持其抗癲癇藥物azetucalnar的III期臨床試驗項目。

The Global Epilepsy Drugs Market is projected to expand from USD 7.16 Billion in 2025 to USD 8.59 Billion by 2031, reflecting a CAGR of 3.08%. This industry sector encompasses the development and sale of anticonvulsant medications and antiseizure therapies intended to regulate neuronal activity and manage the frequency of neurological episodes. Key drivers fueling this growth include the increasing global prevalence of chronic brain disorders and the broader implementation of government-led diagnostic initiatives. According to the World Health Organization, approximately 50 million people worldwide were living with epilepsy in 2024, underscoring the critical and growing demand for effective therapeutic interventions.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 7.16 Billion
Market Size 2031	USD 8.59 Billion
CAGR 2026-2031	3.08%
Fastest Growing Segment	Second Generation Anti Epileptics
Largest Market	North America

A major hurdle hindering market progress is the significant treatment gap existing in developing regions where healthcare infrastructure remains inadequate. This disparity limits patient access to essential medicines and curtails the commercial reach of pharmaceutical manufacturers in emerging economies. Data from the World Health Organization indicates that in 2024, nearly 75% of individuals with epilepsy in low-income countries did not receive necessary medical treatment, representing a substantial barrier to the equitable distribution of antiseizure products.

Market Driver

The increasing global incidence of epilepsy and seizure disorders serves as a primary catalyst for market expansion, elevating the volume of patients requiring long-term pharmacological management. As prevalence grows due to genetic factors and acquired brain injuries, the demand for effective anticonvulsant therapies is intensifying across all patient demographics. This expanding patient pool necessitates higher production capacities and sustained supply chains for essential medications. As noted by the Centers for Disease Control and Prevention in their May 2024 'Epilepsy Basics' update, roughly 3 million adults in the United States reported having active epilepsy, highlighting the substantial demand for seizure control interventions and ensuring a stable commercial foundation for manufacturers to scale their therapeutic portfolios.

Simultaneously, advancements in third-generation anti-epileptic drug formulations are boosting market value by addressing critical unmet needs in treatment-resistant epilepsy. These novel formulations offer precision mechanisms to target specific syndromes, providing effective options for patients unresponsive to standard care. The commercial success of these specialized therapies highlights the market's shift towards high-value treatments over generic alternatives. For instance, Jazz Pharmaceuticals reported in its 'Third Quarter 2024 Financial Results' in November 2024 that net product sales for Epidiolex increased by 18% to $251.6 million. Similarly, UCB announced in its 'Half-Year Report 2024' in July 2024 that net sales for Fintepla reached €154 million in the first six months, reflecting the robust trajectory driven by innovative drugs tailored to complex neurological profiles.

Market Challenge

The profound treatment gap and insufficient healthcare infrastructure in developing regions function as severe restraints on the Global Epilepsy Drugs Market. This structural deficiency directly curtails the commercial potential of pharmaceutical manufacturers by physically and economically preventing the distribution of anticonvulsant therapies to a majority of the global patient population. Without robust diagnostic networks and reliable supply chains, the effective addressable market shrinks significantly, as millions of potential consumers remain undiagnosed or unable to obtain consistent prescriptions. This inability to penetrate high-prevalence emerging markets stagnates revenue volume and forces companies to rely disproportionately on saturated developed economies.

The magnitude of this restriction is evident in recent data regarding medication accessibility. According to the International League Against Epilepsy, in 2023, only one in five people with epilepsy globally had access to affordable anti-seizure medicines. This statistic indicates that despite the high prevalence of the condition, the actual commercial reach of the industry is effectively capped at a fraction of total demand. Consequently, this disparity creates a tangible ceiling for market valuation and expansion, directly limiting the financial performance of the sector.

Market Trends

The integration of digital health and wearable monitoring technologies is fundamentally reshaping patient care by shifting focus from reactive treatment to proactive, holistic management. This trend involves the deployment of AI-driven platforms and smart devices that continuously track seizure activity, enabling real-time data sharing between patients and neurologists to optimize therapeutic outcomes. Pharmaceutical companies are increasingly capitalizing on this synergy by establishing commercial entities dedicated to digital therapeutics, thereby extending their value proposition beyond traditional medication. For instance, in October 2025, SK Biopharmaceuticals established a joint venture named Mentis Care with Eurofarma to commercialize an artificial intelligence-based epilepsy management platform aimed at providing seizure detection and personalized care solutions.

Simultaneously, there is an intensified R&D focus on drug-resistant epilepsy therapies, driven by the need to support patients who do not respond to existing standard-of-care medications. Manufacturers are heavily investing in clinical pipelines to develop novel small molecule candidates with unique mechanisms of action, such as potassium channel openers, to address focal onset seizures and other refractory conditions. This strategic commitment is evidenced by substantial capital allocation toward late-stage clinical trials intended to bring these next-generation treatments to market. According to Xenon Pharmaceuticals, in its 'Fourth Quarter and Full Year 2024 Financial Results' released in February 2025, the company reported a cash and investment position of $754.4 million to largely support the advancement of its Phase 3 epilepsy program for azetukalner.

Key Market Players

Novartis AG
GlaxoSmithKline plc
Sanofi S.Aa
UCB S.A.
Abbott Laboratories
Bausch Health Companies, Inc
Viatris Inc.
Johnson & Johnson
Sumitomo Pharma Co., Ltd
H. Lundbeck A/S

Report Scope

In this report, the Global Epilepsy Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Epilepsy Drugs Market, By Drugs

First Generation Anti-epileptics
Second Generation Anti-epileptics
Third Generation Anti-epileptics

Epilepsy Drugs Market, By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Epilepsy Drugs Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Epilepsy Drugs Market.

Available Customizations:

Global Epilepsy Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Epilepsy Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drugs (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics)
- 5.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Epilepsy Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drugs
- 6.2.2. By Distribution Channel
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Epilepsy Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drugs
    - 6.3.1.2.2. By Distribution Channel
- 6.3.2. Canada Epilepsy Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drugs
    - 6.3.2.2.2. By Distribution Channel
- 6.3.3. Mexico Epilepsy Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drugs
    - 6.3.3.2.2. By Distribution Channel

7. Europe Epilepsy Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drugs
- 7.2.2. By Distribution Channel
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Epilepsy Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drugs
    - 7.3.1.2.2. By Distribution Channel
- 7.3.2. France Epilepsy Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drugs
    - 7.3.2.2.2. By Distribution Channel
- 7.3.3. United Kingdom Epilepsy Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drugs
    - 7.3.3.2.2. By Distribution Channel
- 7.3.4. Italy Epilepsy Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drugs
    - 7.3.4.2.2. By Distribution Channel
- 7.3.5. Spain Epilepsy Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drugs
    - 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Epilepsy Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drugs
- 8.2.2. By Distribution Channel
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Epilepsy Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drugs
    - 8.3.1.2.2. By Distribution Channel
- 8.3.2. India Epilepsy Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drugs
    - 8.3.2.2.2. By Distribution Channel
- 8.3.3. Japan Epilepsy Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drugs
    - 8.3.3.2.2. By Distribution Channel
- 8.3.4. South Korea Epilepsy Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drugs
    - 8.3.4.2.2. By Distribution Channel
- 8.3.5. Australia Epilepsy Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drugs
    - 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Epilepsy Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drugs
- 9.2.2. By Distribution Channel
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Epilepsy Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drugs
    - 9.3.1.2.2. By Distribution Channel
- 9.3.2. UAE Epilepsy Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drugs
    - 9.3.2.2.2. By Distribution Channel
- 9.3.3. South Africa Epilepsy Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drugs
    - 9.3.3.2.2. By Distribution Channel

10. South America Epilepsy Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drugs
- 10.2.2. By Distribution Channel
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Epilepsy Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drugs
    - 10.3.1.2.2. By Distribution Channel
- 10.3.2. Colombia Epilepsy Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drugs
    - 10.3.2.2.2. By Distribution Channel
- 10.3.3. Argentina Epilepsy Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drugs
    - 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Epilepsy Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Novartis AG
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. GlaxoSmithKline plc
15.3. Sanofi S.Aa
15.4. UCB S.A.
15.5. Abbott Laboratories
15.6. Bausch Health Companies, Inc
15.7. Viatris Inc.
15.8. Johnson & Johnson
15.9. Sumitomo Pharma Co., Ltd
15.10. H. Lundbeck A/S